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Lipid emulsions (LE) for parenteral use are complex emulsions containing fatty acids, glycerol,
phospholipids and tocopherol in variable amounts and concentrations. In clinical practice, LE
have been employed for more than 30 years. Fatty acids may have different impacts on
phagocytic cells according to their structure. Experimental and clinical studies have consistently
shown that LE modify monocyte/macrophage and polymorphonuclear phagocytosis. The
inhibitory effect of LE on the functional activity of the phagocytic system, although still
clinically controversial, may have a harmful impact because total parenteral nutrition with lipids
may be recommended in hypercatabolic conditions where inflammation and infection are present.
LE based on triglycerides containing long chain fatty acids (termed long chain triglycerides or
LCT) are the main parenteral fat source and are typically rich in n-6 polyunsaturated fatty acids.
They may have adverse effects on the immune system, especially when given in high doses over a
short period of time. However when administered properly they can be used safely. LE
containing medium chain triglycerides (MCT) may have some advantages because of their
positive effects on polymorphonuclear cells, macrophages, and cytokine production, particularly
in critically ill or immunocompromized patients. New parenteral LE containing n-3
polyunsaturated fatty acids or monounsaturated olive oil are already available in Europe.
Judicious use of these new LE is mandatory especially relating on their potential impact on the
immune system. New experimental and clinical studies are required to further establish the role
of LE in clinical nutrition.
Parenteral nutrition: Macrophage: Lipid: Neutrophil: Phagocytosis
General considerations
Indian scriptures dating back to 5000 BC have documented
that nutritional status has been associated with health
(Chandra, 1985). Nutritional depletion results in immuno-
suppression, and therefore host defense impairment,
favoring increased infection and mortality rates (Mullen
et al. 1980). Improvement of nutritional state with
nutritional interventions may re-establish immune compe-
tence and decrease the frequency and severity of infectious
complications in hospitalized patients (Dudrick et al. 1969).
Total parenteral nutrition (TPN) is one well-established
nutritional therapy, which allows intravenous feeding of
patients without an available enteral route (Koss et al.
1979). TPN is widely applied in hospital settings and
consists of a solution containing amino acids, glucose,
electrolytes and vitamins as well as lipid emulsions (LE). In
TPN regimens, LE function as calorie dense nutrients and a
source of essential fatty acids.
Fatty acids (FA) are the main component of cell
membranes. They are responsible for membrane structural
integrity and the production of eicosanoids. Lipids are
also major metabolic regulators and can modulate the
immune response (Meade & Mertin, 1978; DeWille et al.
1979; Kinsella, 1990).
Research on the effects of fatty acids on the immune
response date back for over 30 years (Piette & Saugier,
1970; Mertin & Meade, 1977). The impact of intravenously
infused isolated fatty acids on the immune system has been
studied since 1972 (Di Luzio, 1972). It is well known that
changes in the quality and amount of dietary fat (Hwang,
1989), as well as abnormalities in lipid metabolism (Koss
et al. 1979; Beisel, 1981) can alter the immune response.
There is much evidence that LE also have an impact on
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mononuclear phagocytic function, particulary phago-
cytosis (Strunk et al. 1979; Wiernik et al. 1983; Cleary
& Pickering, 1983; Waitzberg et al. 1996). The purpose
of this review is to examine the effects of different LE
on the phagocytic process of macrophages and poly-
morphonuclear cells.
Lipid emulsions
LE are the parenteral source of essential fatty acids. They
can be infused alone or together with glucose and amino
acids, in malnourished or hypercatabolic patients. LE are
triglyceride droplets enveloped with a stabilizing superficial
layer of phospholipids (Shils et al. 1998) and their
formulation includes substances other than triglycerides,
such as lecithin, glycerol and alpha-tocopherol in variable
amounts. The triglycerides may be presented structurally as
long chain triglycerides (LCT) or medium chain triglycer-
ides (MCT). LCT LE have been used in clinical practice for
over 30 years. LCT contain fatty acid chains with 14, 16, 18,
20 and 22 carbon atoms and sometimes with double bonds.
The number of double bonds present defines the fatty acids
in LCT as saturated, mono or polyunsaturated. The double
bonds can be found in different places in the carbon chain,
their position follows rules governed by the specificity of
the enzymes responsible for inserting them. If the first
double bond is on carbon number 3, 6 or 9 from the methyl
end of the carbon chain then the fatty acid is n-3, n-6 or n-9,
respectively. LE which are commercially available for
parenteral use are based on LCT containing a high
proportion of n-6 polyunsaturated fatty acids usually
derived from soybean or safflower oil, although LCT
containing n-3 polyunsaturated fatty acids, derived from fish
oil, and n-9 monounsaturated fatty acids from olive oil are
also available. Saturated fatty acids with chains containing
6, 8, 10 or 12-carbon atoms form the MCT emulsions. MCT
are found in high amounts in coconut oil. For clinical
purposes MCT is used as a 50 % physical or structured
mixture with LCT. Thus MCT/LCT LE have a lower
proportion of LCT volume/volume than LCT LE.
Recently in Europe LE containing LCT or LCT/MCT
enriched with fish oil (FO) became available for research.
FO includes long chain triglycerides with twenty or more
carbon atoms where the first double bond is located between
the third and the fourth carbons from the methyl terminal of
the fatty acids chain (omega-3 or n-3).
The incorporation of n-3 fatty acids into macrophage
membranes occurs in 3–6 hours in vitro and in 3 days in
vivo. The incorporation of different fatty acids may
change membrane fluidity, alter phosphatidylinositol
production and dienoic eicosanoid secretion and modulate
the generation of interleukins and tumour necrosis factor
(TNF) in response to lipopolysaccharide (LPS) stimu-
lation. These effects are related to the membrane n-6:n-3
fatty acid ratio and to the total amount of n-3 and n-6 FA
infused.
The physicochemical nature of the infused triacylglycerol
(i.e. carbon chain length, saturation degree, size of the
particle and nature of fatty acid) may determine structural
changes and alterations in the phagocytic cell activity.
Effects of lipid emulsions on monocyte-macrophages
Monocyte-macrophages are immune cells involved in
phagocytosis, antigen presentation and cytokine production.
A number of experimental and clinical studies investigating
the effects of currently used LE on monocyte-macrophage
functions are summarized in Table 1.
Experimental studies
Experimental studies regarding the effects of LE on
phagocytosis by monocyte-macrophages are controversial.
Several trials have used rats, guinea pigs, and mice infused
with different LE alone or as a component of TPN and
studied the effects on circulating and resident macrophages.
Experimental lipid-TPN infusion for a week has been
associated with decreased phagocytosis and increased
superoxide production by peritoneal macrophages, splenic
macrophage proliferation and bacterial translocation (Shou
et al. 1994). Intravenous infusion of LCT LE and MCT/LCT
LE into rats infected by Escherichia coli (E. coli) was
followed by hyperplasia of Kupffer cells and splenic
histiocytes (Waitzberg et al. 1992). The infusion of TPN
with LCT LE into guinea pigs reduced phagocytosis of E.
coli by Kupffer cells and splenic macrophages (Hamawy
et al. 1985).
TPN with LCT LE was associated with inhibition of
pulmonary bacterial phagocytosis but this was not observed
with TPN with MCT/LCT (Sobrado et al. 1985). These
changes were not verified in a similar experimental model in
septic rats infused with TPN containing 50 % non-protein
calories in the form of LCT LE (Vallgren et al. 1986).
Despite reports indicating inhibitory effects of LCT LE,
including anatomical-pathological alterations of monocytes
and macrophages (Strunk et al. 1979; Nugent, 1984), other
evaluations of the effect of LCT and MCT/LCT LE
infusions in animals showed no alterations of phagocytosis
and other monocyte/macrophage functions at different
doses and periods and rates of infusion (Nishiwaki et al.
1986; Allen & Murray, 1986; Waitzberg et al. 1996).
Moreover it seems that there are distinct macrophage
responses to intravenous infusion of LE according to the
anatomical origin of macrophages. The total number of liver
and spleen macrophages were reduced but pulmonary
phagocytosis was increased when TPN enriched with LCT
LE was compared to an oral diet (Cukier et al. 1999). These
differences between studies may be attributed to differences
in the experimental models used, and the amount of lipids
administered (Table 1).
The addition of a fish oil LE to LCT and MCT/LCT LE
increased total liver and lung macrophage number and
phagocytosis in rats after 96 h of intravenous infusion
(Cukier et al. 1999).
Human studies
Not many human clinical studies have investigated the
effects of LE on monocyte function. Wiernik et al. (1983)
infused 20 % soybean oil emulsion intravenously for 2 h into
healthy volunteers. During the infusion a significant
increase in nitroblue tetrazolium-reduction by blood
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Table 1. Studies of lipid emulsions on monocyte/macrophage function
Reference Study in Type of LE Via Dose Time (h) Function Findings
Waitzberg et al. 1997 Gastric cancer
patients
(10) (1TPN)
LCT 10 % i.v. 10 kcal/kg per day
(0:08 g/kg per h)
48 Chemotaxis No alteration
MCT/LCT 10 % Bacterial killing No alteration
Phagocytosis No alteration
Wiernik et al. 1983 Healthy volunteers (18) LCT 20 % i.v. 20–100 mg/ml 0:5 NBT reduction "
Strunk et al. 1979 Guinea pigs LCT 10 % i.v. 93–375 mg/l 48 Ability of peritoneal Mf to spread #
Number of membrane ruffles #
Complexity of membrane ruffles #
Phagocytosis #
Nugent, 1984 Mice LCT i.v. 40 % vol 18 Appearance of peritoneal Mf Rounded and more dense
Phagocytosis #
Pinocytosis #
Allen & Murray, 1986 Mice LCT i.v. 2 g/kg per d 240 PHI No alteration
Liver and spleen size No alteration
Nishiwaki et al. 1986 Septic rats LCT i.v. 25 % of NPC 72 Phagocytosis No alteration
Waitzberg et al. 1992 Rats with E. coli
peritonitis
LCT 10 % i.v. 5 ml/kg per h 44 Chemotaxis No alteration
MCT/LCT 10 % Phagocytosis No alteration
MCT 10 % Bacterial killing No alteration
Cukier et al. 1999 Rats LCT 10 % i.v. 2 ml/kg per h
(31 % of NPC)
96 PHI of liver Mf "
LCT 1 FO (9:1 vol/vol) PHI of liver and lung Mf "
LCT 1 FO (1:1 vol/vol) PHI of liver and lung Mf "
MCT/LCT 1 FO PHI of liver and lung Mf "
(9:1 vol/vol) PHI of liver and lungMf "
Abbreviations used: FO, fish oil; i.v., intravenous; LCT, long chain triglyceride; Mf, macrophages; MCT, medium chain triglyceride; NBT, nitroblue tetrazolium; NPC  non protein calories; PHI  phagocytic index;
TPN, total parenteral nutrition.
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Table 2. Studies of lipid emulsions on PMN function
Reference Study in Type of LE Via Dose
Time
(h) Function Findings
Waitzberg et al. 1992 Rats with E. coli LCT 10 % i.v. 0:5 ml/kg per h 44 Chemotaxis No alteration
Periotonitis MCT/LCT 10 % Phagocytosis No alteration
MCT 10 % Bacterial killing No alteration
Waitzberg et al. 1996 Rats LCT 10 % i.v. 1 ml/h 30 Phagocytosis No alteration
MCT/LCT 10 % 1 or 1:5 ml/h 44 Chemotaxis No alteration
Rats LCT 10 % i.v. 20 mg/ml 0:5 Phagocytosis # (LCT & MCT/LCT)
MCT 10 % Bacterial killing # (MCT)
MCT/LCT 10 % Chemotaxis # (MCT)
Jarstrand et al. 1978 Healthy volunteers LCT 20 % i.v. 20–100 mg/ml 0,5 NBT reduction #
Bacterial killing #
Patients (8) LCT 20 % i.v. 100 ml/h 1 NBT reduction #
Patients (6) LCT 20 % i.v. 100 ml/h 1 Bacterial killing #
Nordenstrom et al.
1979
Healthy volunteers (12) LCT 20 % i.v. 50–200 ml/h 2 Chemotaxis # (dose dependent)
Fischer et al. 1980 Healthy volunteers LCT i.v. 12:5–100 mg/ml 0:5 Chemotaxis #
English et al. 1981 Healthy volunteers LCT 10 % i.v. 80 mg/ml 0:5 Chemotaxis # if LCT not dialysed
Superoxide production # if LCT not dialysed
Chemiluminescence # if LCT not dialysed
No alteration if LCT dialysed against
saline
Palmblad et al. 1982 Crohn’s Disease (4) LCT 20 % i.v. 21 ml/h 10 Bacterial killing No alteration
Healthy volunteers (10) LCT 20 % i.v. 85 ml/h 6 Chemiluminescence No alteration
Chemotaxis "
Wiernik et al. 1983 Healthy volunteers (18) LCT 20 % i.v. 20–100 mg/ml 0:5 NBT reduction #
Chemotaxis #
Cleary et al. 1983 Healthy volunteers LCT10 % i.v. 15–100 mg/ml 0:5 NBT reduction " (dose dependent)
O2 consumption " (dose dependent)
Bacterial killing " (dose dependent)
Phagocytosis " (dose dependent)
But # of all functions with high dose
Ota et al. 1985 Cancer patients (40) LCT 20 %
(1TPN)
i.v. 500 ml/day 240 Phagocytosis No alteration
Chemotaxis No alteration
Bacterial killing No alteration
Escudier et al. 1986 Surgical cancer patients
(9)
LCT 20 %
(1TPN)
i.v. 83 ml/h 6 Chemotaxis No alteration
Rasmussen et al. 1988 Minor surgical patients
(24)
LCT 20 % i.v. 100 ml/h 4 Opsonization time No alteration
O2 consumption No alteration
Superoxide production No alteration
Phagocytosis No alteration
Candida albicans killing No alteration
Chemotaxis No alteration
Monico et al. 1988 Healthy volunteers (40) MCT/LCT 10 % i.v. 120 ml/h 5–7 Chemotaxis No alteration
Adherence to nylon
fibers
No alteration
Phagocytosis No alteration
Robin et al. 1989 Patients (25) LCT10 % i.v. 100 ml/h 4–6 Chemiluminescence #
Healthy volunteers (10) LCT 10 % i.v. 400 mg/l 0:75 Chemiluminescence No alteration
Herson et al. 1989 Ill neonates (10) LCT i.v. 1 g/kg 16 Chemotaxis No alteration
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Table 2. Continued
Reference Study in Type of LE Via Dose Time
(h)
Function Findings
i.v. 100 mg/ml 0:5 Chemotaxis No alteration
Bellinatti-Pires et al.
1992
Healthy volunteers LCT 10 % i.v. 20 mg/ml 0:5 Chemotaxis # (dose dependent) in MCT groups
MCT 10 %
MCT/LCT 10 %
Bellinatti-Pires et al.
1993
Healthy volunteers (20) LCT 10 % i.v. 20 mg/ml 0:5 NBT reduction # in MCT groups
MCT 10 % Phagocytosis # in MCT groups
MCT/LCT 10 % H2O2 production # in MCT groups
Bacterial killing # in MCT groups
Waitzberg et al. 1997 Gastric cancer patients
(10)
LCT 10 % i.v. 10 kcal/d (0:08 g/kg per
h)
48 Chemotaxis No alteration
MCT/LCT 10 % NBT reduction No alteration
(1TPN) Bacterial killing #
Heine et al. 1999 Healthy volunteers (10) LCT i.v. 60–600 mg/ml ,0:5 Respiratory burst #
MCT/LCT "
LCT with FO #
Kruimel et al. 2000 Healthy volunteers LCT i.v. 1–100 mmol/l 0:5 Chemiluminescence " with MCT/LCT
MCT/LCT ROS production " rate and amount with
MCT/LCT
structured
MCT/lLCT
Abbreviations used: FO, fish oil; i.v., intravenous; LCT, long chain triglyceride; MCT, medium chain triglyceride; NBT, nitroblue tetrazolium; TPN, total parenteral nutrition.
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monocytes was noted. Preincubation of monocytes in vitro
with LCT LE (20–100 mg/ml) for 30 min was found to
increase the ability of the cells to migrate chemotactically
and to phagocytose yeast particles.
In a prospective, randomized, cross-over clinical trial
malnourished gastric cancer patients received a 48 h TPN
(40 kcal/kg) with 25 % of energy provided as LCT or
MCT/LCT LE (infused at the rate of 0:08 g/kg per h). No
alteration in monocyte-macrophage function and phagocy-
tosis was found with either LE compared to the appropriate
controls (Waitzberg et al. 1997).
Effects of lipid emulsions on neutrophils
Neutrophils are cells related to natural immunity. They
represent the first cellular defense against microorganisms.
Their initial functions are to phagocytose and inactivate
invasive agents. Despite numerous reports about inter-
actions between lipids and the phagocytic system, the
effects of LE on the metabolic and microbial killing
activities of neutrophils are still controversial (Table 2).
Experimental studies
Experimental data indicate an inhibitory effect of LCT and
MCT/LCT LE on rat neutrophil phagocytosis in vitro
(Waitzberg et al. 1996), but no differences in ex vivo
phagocytosis, chemotaxis and bacterial killing were
observed in healthy and septic rats when LCT LE,
MCT/LCT LE or saline were intravenously administrated
(Waitzberg et al. 1992, 1996).
From the in vitro studies performed using human
polymorphonuclear cells a dose dependent response to LE
is apparent. For instance, soybean oil emulsions showed an
inhibitory effect on neutrophils when used at concentrations
ranging from 15 mg/ml to 100 mg/ml but when concen-
trations higher than 100 mg/ml were used, no alterations in
neutrophil functions were found (Jarstrand et al. 1978;
Wiernik et al. 1983; English et al. 1981; Bellinati-Pires et al.
1992). Moreover, with MCT/LCT LE a stimulatory effect
was documented (Robin et al. 1989; Bellinati-Pires et al.
1992; Bellinati-Pires et al. 1993; Heine et al. 1999), when
low doses were used.
In clinical studies, the capacity of neutrophils to
phagocytose was not altered with LCT LE (Ota et al.
1985; Rasmussen et al. 1988), or MCT/LCT (Monico et al.
1988; Dominioni & Dionigi, 1987). Chemotaxis was also
unchanged in five studies with LCT-LE (Ota et al. 1985;
Rasmussen et al. 1988; Escudier et al. 1986; Herson et al.
1989; Waitzberg et al. 1997). However, a dose-dependent
inhibitory effect was detected in a single study
(Nordenstrom et al. 1979) and also the opposite, a
stimulatory effect, has been demonstrated. (Palmblad et al.
1982). Bacterial killing by polymorphonuclear neutrophils
(PMN) is controversial: three studies did not find any
alteration (Ota et al. 1985; Palmblad et al. 1982; Rasmussen
et al. 1988) and two studies showed an inhibition with LCT
LE (Jarstrand et al. 1978; Waitzberg et al. 1997). In a
clinical trial with gastric cancer patients receiving TPN with
LCT or MCT/LCT LE, bacterial killing by neutrophils was
the only function reduced after LCT LE, although this
function remained within the normal range values in 80 % of
the patients. In conclusion, LCT LE moderately decreases
neutrophil bacterial killing.
There is little literature involving nitroblue-tetrazolium
(NBT) reduction and superoxide anion production.Two
studies showed no change (Rasmussen et al. 1988;
Waitzberg et al. 1997) and one study an inhibitory effect
(Jarstrand et al. 1978).
There are no data available regarding the effect of n-3
fatty acid-containing LE or olive oil emulsion on neutrophil
function.
Potential immunomodulatory mechanisms
of lipid emulsions
In the last years, several mechanisms have been proposed to
explain the different effects of LE on the immune system.
They are associated mainly with fatty acid incorporation
and modification of cell membrane composition (Palombo
et al. 1997).
The effects of fatty acids on phagocytic activity in vivo
and in vitro are controversial. The presence of dietary
polyunsaturated fatty acids may inhibit microbicidal
activity. However, polyunsaturated fatty acids may
stimulate this activity when directly added to cell culture.
One possible explanation for the controversial results is
provided by Mahoney et al. (1977, 1980). These authors
calculated that, in normal conditions, the phagocytosis of an
erythrocyte results in approximately 7 % internalization of
the macrophage surface area.
Membrane fatty acid composition influences membrane
fluidity, cell permeability, eicosanoid production, as well as
membrane receptors, enzymes and second messenger
signaling processes. Although n-6 and n-3 polyunsaturated
fatty acids are incorporated into cell membranes, it remains
to be proved if medium chain triglycerides or saturated fatty
acids are also incorporated into cell membranes when
present in doses higher than in a normal diet. Fatty acids
may interfere with other immune modulating mechanisms
such as modulation of adhesion molecules, regulation of
nitric oxide (NO) production, modulation of signal
transduction pathways and direct modulation of gene
expression (Yaqoob, 1998).
Enzymes such as lipoxygenases and cyclooxygenases
produce proinflammatory lipid mediators such as leuko-
triene (LT) B4 and prostaglandin (PG) E2 from arachidonic
acid. Several eicosanoids such as LTB4 and thromboxane B2
(TXB2) have chemotactic effects. When exposed to higher
concentrations of n-3 polyunsaturated fatty acids, lipoxy-
genases and cyclooxygenases produce less biologically
active mediators as LTB5 and PGE3 (Magrum & Johnston,
1983). An n-3 fatty acid rich diet lowers PGE2, 6-keto-
PGF1-alpha, LTB4 and TXB2 production when compared to
an n-6 fatty acid rich diet. n-6 Fatty acids augment PGE2,
LTB4, LTC4, LTD4, 6-keto-PGF1-alpha and TXB2,
probably via arachidonic acid, the eicosanoid precursor.
Membrane phospholipids can be transformed by phos-
pholipases to yield second messengers (such as phospha-
tidylinositol-4,5-bisphosphate generating diacylglycerol
and inositol-1,4,5-trisphosphate) and can be involved in
activating or stabilizing enzymes in signaling pathways
D. L. Waitzberg et al.S54
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(such as phophatidylserine that is required for the activation
of protein kinase C). All phospholipids and some of the
second messengers that they generate contain fatty acyl
chains, and it is possible that changes in membrane fatty
acid composition may alter properties of these compounds.
(Serhan et al. 1996; Ballou et al. 1996; Yaqoob, 1998).
Recent evidence shows that lipids are direct modulators
of gene expression. Therefore, changes in cellular fatty acid
profiles or in fatty acid metabolites could affect the activity
of specific transcription factors, which alter gene transcrip-
tion (indirect modulation of gene expression). The
peroxisome proliferator-activated receptor family (PPAR
– a group of key nuclear receptors involved in the regulation
of lipid homeostasis) regulate the expression of target genes
by binding to DNA sequence elements. It has been shown
that several unsaturated fatty acids bind directly to PPAR-
alpha (Yaqoob, 1998). Through these actions fatty acids
could regulate expression of adhesion proteins, such as
integrins and selectins, thus altering cell adhesion.
NADPH oxidase is an enzyme present in neutrophils
which produces free radicals and may be stimulated by
arachidonic acid. Diets enriched with n-6 or saturated fatty
acids are associated with decreased peroxide and free
radical production by activated neutrophils and to down
regulation of glucose-6-phosphate-dehydrogenase. The
latter is one of the most powerful inducers of NADPH
synthesis, and an essential substrate for free radical
production by NADPH oxidase. NO production is catalysed
in phagocytic cells by NO synthetase induction. Transcrip-
tion of NO synthetase and NO production may be inhibited
by polyunsaturated fatty acids.
Despite the different immunomodulating properties of
fatty acids it should be kept in mind that LE for parenteral
use are complex nutrient sources composed not only of fatty
acids but also including phosphatidylcholine, glycerol, and
a-tocopherol. Besides that, LE contain various types of
triglycerides in a physical or structured mixture. The
interaction of these distinct substances may alter the effects
observed with isolated fatty acids (Kruimel et al. 2000; De
la Fuente, 2000).
Clinical impact and conclusions
In clinical practice, LE for parenteral use have been
employed for more than 30 years. The inhibitory effect of
LE on the functional activity of the phagocytic system,
although still controversial, may be an important harmful
impact because TPN with lipids may be recommended in
hypercatabolic conditions where inflammation and infection
are present.
LCT LE are still the main parenteral fat source and are
rich in n-6 fatty acids. The concerns about the association of
LE with infectious morbidity were raised after a report of an
increased risk of bacteriemia related to the use of LE in
neonates (Freeman et al. 1990). However in an extensive
clinical trial in patients undergoing bone marrow transplan-
tation while receiving TPN there was no evidence that
moderate doses of a LCT LE were associated with the
incidence of bacterial or fungal infections (Lenssen et al.
1998).
LCT LE may have adverse effects on the immune system,
especially when they are given in high doses over a short
period of time. However, when administered properly they
can be used safely for clinical purposes (Klein & Miles,
1994).
MCT containing LE, in a physical or structured way, may
bring some advantages because of their positive effects on
polymorphonuclear cells, macrophages, and cytokine
production, particularly in critically ill or immunocompro-
mized patients. This is one of the reasons to consider
substitution of LCT LE with MCT/LCT LE. Accordingly,
there is a tendency to prefer MCT/LCT emulsions in
critically ill patients before and after surgery and in sepsis.
LCT LE should be limited in specific clinical conditions like
burns, cancer, hepatic dysfunction, immunocompromized
status and metabolic stress.
On the other hand, fish oil containing LE, may have some
advantages in patients with autoimmune diseases such as
rheumatoid arthritis and intestinal inflammatory diseases or
in special clinical situations where an anti-inflammatory
activity is desirable (Calder, 1998).
In spite of the optimistic preliminary results concerning
the parenteral use of olive oil, its effects need to be
confirmed by more prospective, randomized clinical trials.
Variables like amount, and type of fatty acids, infusion rates
and TPN duration should also be considered.
New parenteral lipid emulsions containing n-3 poly-
unsaturated fatty acids and monounsaturated olive oil are
already available in Europe. Judicious use of these new LE
is mandatory especially relating to the impact on the
immune system. New experimental and clinical studies are
required to further establish the role of LE in clinical
nutrition.
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